160 related articles for article (PubMed ID: 19748172)
1. In search of the perfect crystal ball for Ta urothelial cancer.
Chin JL
Eur Urol; 2010 Jan; 57(1):21-2; discussion 23-4. PubMed ID: 19748172
[No Abstract] [Full Text] [Related]
2. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
Birkhahn M; Mitra AP; Williams AJ; Lam G; Ye W; Datar RH; Balic M; Groshen S; Steven KE; Cote RJ
Eur Urol; 2010 Jan; 57(1):12-20. PubMed ID: 19762144
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
Colombo R
Eur Urol; 2010 Jan; 57(1):93-4. PubMed ID: 19345471
[No Abstract] [Full Text] [Related]
4. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.
Burger M; Oosterlinck W; Konety B; Chang S; Gudjonsson S; Pruthi R; Soloway M; Solsona E; Sved P; Babjuk M; Brausi MA; Cheng C; Comperat E; Dinney C; Otto W; Shah J; Thürof J; Witjes JA;
Eur Urol; 2013 Jan; 63(1):36-44. PubMed ID: 22981672
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
6. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
7. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis and diagnostics of bladder cancer.
Mitra AP; Cote RJ
Annu Rev Pathol; 2009; 4():251-85. PubMed ID: 18840072
[TBL] [Abstract][Full Text] [Related]
9. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
10. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
11. [Studies on multiple mucosal biopsy in patients with bladder cancer. 2. Evaluation on the relationship between the results of multiple mucosal biopsy and recurrence, and the clinical course of cases with carcinoma in situ and micro-invasion of carcinoma in situ].
Igawa M
Hinyokika Kiyo; 1986 Nov; 32(11):1633-47. PubMed ID: 3825813
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
14. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
15. The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.
Lopez-Beltran A; Luque RJ; Moreno A; Bollito E; Carmona E; Montironi R
Virchows Arch; 2002 Aug; 441(2):148-53. PubMed ID: 12189504
[TBL] [Abstract][Full Text] [Related]
16. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in molecular profiling of bladder cancer.
Ørntoft TF; Zieger K; Dyrskjøt L
Curr Opin Urol; 2006 Sep; 16(5):377-81. PubMed ID: 16905986
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
Copp HL; Chin JL; Conaway M; Theodorescu D
Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
[TBL] [Abstract][Full Text] [Related]
19. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
20. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
